Paradoxical Effect of Chloroquine Treatment in Enhancing Chikungunya Virus Infection
Open accessThe DOI matches its Crossref record.
Abstract
Since 2005, Chikungunya virus (CHIKV) re-emerged and caused numerous outbreaks in the world, and finally, was introduced into the Americas in 2013. The lack of CHIKV-specific therapies has led to the use of non-specific drugs. Chloroquine, which is commonly used to treat febrile illnesses in the tropics, has been shown to inhibit CHIKV replication in vitro. To assess the in vivo effect of chloroquine, two complementary studies were performed: (i) a prophylactic study in a non-human primate model (NHP); and (ii) a curative study “CuraChik”, which was performed during the Reunion Island outbreak in 2006 in a human cohort. Clinical, biological, and immunological data were compared between treated and placebo groups. Acute CHIKV infection was exacerbated in NHPs treated with prophylactic administration of chloroquine. These NHPs displayed a higher viremia and slower viral clearance (p < 0.003). Magnitude of viremia was correlated to the type I IFN response (Rho = 0.8, p < 0.001) and severe lymphopenia (Rho = 0.8, p < 0.0001), while treatment led to a delay in both CHIKV-specific cellular and IgM responses (p < 0.02 and p = 0.04, respectively). In humans, chloroquine treatment did not affect viremia or clinical parameters during the acute stage of the disease (D1 to D14), but affected the levels of C-reactive Protein (CRP), IFNα, IL-6, and MCP1 over time (D1 to D16). Importantly, no positive effect could be detected on prevalence of persistent arthralgia at Day 300. Although inhibitory in vitro, chloroquine as a prophylactic treatment in NHPs enhances CHIKV replication and delays cellular and humoral response. In patients, curative chloroquine treatment during the acute phase decreases the levels of key cytokines, and thus may delay adaptive immune responses, as observed in NHPs, without any suppressive effect on peripheral viral load.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Alhazzani, W., Møller, M. H., Arabi, Y. M., Loeb, M., Gong, M. N., Fan, E., Oczkowski, S., Levy, M. M., Derde, L., Dzierba, A., et al. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-06022-5 · Cited by 2,105
“In one non-human primate model of chikungunya infection, it was shown that chloroquine's immunomodulatory effects were associated with delayed immune responses, higher levels of viral replication, and worse illness [210] .”
Alhazzani, W., Møller, M. H., Arabi, Y. M., Loeb, M., Gong, M. N., Fan, E., Oczkowski, S., Levy, M. M., Derde, L., Dzierba, A., et al. (2020) · Critical Care Medicine · doi:10.1097/ccm.0000000000004363 · Cited by 1,565
Molina, J. M., Delaugerre, C., Le Goff, J., Mela-Lima, B., Ponscarme, D., Goldwirt, L., & de Castro, N. (2020) · Médecine et Maladies Infectieuses · doi:10.1016/j.medmal.2020.03.006 · Cited by 749
Touret, F., & de Lamballerie, X. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104762 · Cited by 541
Self-citationSingh, A. K., Singh, A., Shaikh, A., Singh, R., & Misra, A. (2020) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2020.03.011 · Cited by 488
COVID-19 infection and rheumatoid arthritis: Faraway, so close
Favalli, E. G., Ingegnoli, F., De Lucia, O., Cincinelli, G., Cimaz, R., & Caporali, R. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102523 · Cited by 454
Chloroquine and hydroxychloroquine in covid-19
Ferner, R. E., & Aronson, J. K. (2020) · BMJ · doi:10.1136/bmj.m1432 · Cited by 403
Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates
Maisonnasse, P., Guedj, J., Contreras, V., Behillil, S., Solas, C., Marlin, R., Naninck, T., Pizzorno, A., Lemaitre, J., Gonçalves, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2558-4 · Cited by 334
Self-citationInsights from nanomedicine into chloroquine efficacy against COVID-19
Hu, T. Y., Frieman, M., & Wolfram, J. (2020) · Nature Nanotechnology · doi:10.1038/s41565-020-0674-9 · Cited by 317
Chiotos, K., Hayes, M., Kimberlin, D. W., Jones, S. B., James, S. H., Pinninti, S. G., Yarbrough, A., Abzug, M. J., MacBrayne, C. E., Soma, V. L., et al. (2020) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piaa045 · Cited by 183
Novel coronavirus 2019 (COVID-19): A case report and review of treatments
Douedi, S., & Miskoff, J. (2020) · Medicine · doi:10.1097/md.0000000000020207 · Cited by 135
Chandler, L., Yusuf, I., McClements, M., Barnard, A., MacLaren, R., & Xue, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21144972 · Cited by 49
Persistent Joint Pain Following Arthropod Virus Infections
Suchowiecki, K., Reid, S. P., Simon, G. L., Firestein, G. S., & Chang, A. (2021) · Current Rheumatology Reports · doi:10.1007/s11926-021-00987-y · Cited by 37
Metadata
- Authors
- Roques, P., Thiberville, S.-D., Dupuis-Maguiraga, L., Lum, F.-M., Labadie, K., Martinon, F., Gras, G., Lebon, P., Ng, L. F. P., De Lamballerie, X., & Le Grand, R.
- Venue
- Viruses
- Publisher
- MDPI AG
- Published
- 2018-05-17
- Volume
- 10
- Issue
- 5
- Pages
- 268
- ISSN
- 1999-4915 (ISSN-L)
- OpenAlex
- W2804754774
- Cited by
- 152
- References
- 0
- FWCI
- 25.11
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.